BioGX developed the assay for the BD MAX™ System in their Sample-Ready™ ready-to-use format to detect the presence of the SARS-CoV-2 virus, the cause of COVID-19. The assay is based on the same viral RNA targeting sequences and real-time PCR detection method as the test developed by the U.S. Centers for Disease Control and Prevention (CDC). Biosurgery To the most sensitive tests go the spoils. Biosciences About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. Patient monitoring and temperature management View original content to download multimedia:http://www.prnewswire.com/news-releases/bd-biogx-announce-fda-emergency-use-authorization-for-new-covid-19-diagnostic-for-use-in-us-301034652.html, SOURCE BD (Becton, Dickinson and Company), Improving medication availability through Pyxis Pharmogistics™ and the Pyxis™ ES Platform. BioGX operates in a cGMP compliant environment certified to International Standard ISO 13485. Biosurgery The company applies its proprietary platform-agnostic reagent technology to offer products and contract services across a variety of real-time PCR and Next Generation Sequencing platforms. BioGX developed the assay for the BD MAX™ System in their Sample-Ready™ ready-to-use format to detect the presence of the SARS-CoV-2 virus, the cause of COVID-19. Learn More. For U.S. customers, an up-to-date list of products on manual inventory allocation can be found at bd.com/allocation. Infusion therapy The BD MAX™ System can process 24 samples simultaneously. It was previously known as 2019 Novel coronavirus (2019-nCov). No Problem. The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. The assay is based on the same viral RNA targeting sequences and real-time PCR detection method as the test developed by the U.S. Centers for Disease Control and Prevention (CDC). Prostate health This kit enables BD MAX System users to run a single module that tests for COVID-19 and Influenza (Flu), along with Respiratory Syncytial Virus (“RSV”) at once. Medication and supply management Medication management It is a versatile, digitally analyzed system that removes result ambiguity and provides lab level performance with assays for SARS-CoV-2, Flu A+B, Group A Strep and RSV. Hazardous drug safety Surgical instruments Capability Ordering For more information on BioGX, please visit BioGX.com. Infection prevention Like the initial test for COVID-19 developed by the CDC, the vast majority of COVID-19 tests being used in the U.S. employ a common technology, called polymerase chain reaction, or PCR. SARS-CoV-2 is the virus responsible for COVID-19. The LIAISON ® MDX is an innovative and powerful thermocycler with two consumable disc options: the 8-well Direct Amplification Disc for sample-to-answer testing and the 96-well Universal Disc for higher volume testing. For more information on BD, please visit bd.com. Specimen collection Each BD MAX System can process 24 samples simultaneously. The Sample-ReadyTM technology is at the core of all product offerings for Clinical, Food Safety, Pharma and Water Quality molecular testing. BioGX developed the assay for the BD MAX™ System in their Sample-Ready™ ready-to-use format to detect the presence of the SARS-CoV-2 virus, the cause of COVID-19. This kit enables BD MAX System users to run a single module that tests for COVID-19 and Influenza (Flu), along with Respiratory Syncytial Virus (“RSV”) at once. All of our global manufacturing and distribution centers are operational at this time, with the vast majority of critical-to-COVID sites operating at or near full capacity. Hernia repair and fixation BD BioGX SARS-CoV-2 for BD MAX ™ System However, it has been authorized by the FDA under an EUA. Clinically trained associates in sites around the world are volunteering their time to augment hospital staff in communities hard-hit by COVID-19; and associates from a broad range of disciplines are delivering virtual trainings to teach community and non-profit organizations how to contain its spread. We are providing this page as a single source for all SARS-CoV-2/COVID-19 LOINC content. Respiratory care The BD Veritor™ Plus System is the portable, easy-to-use testing system that delivers reliable results in just minutes. ... BioGX SARS CoV-2 test for the BD MAX … We are actively monitoring our global logistics and transportation network, taking necessary actions to work around global capacity and border constraints to minimize the risk of any customer delays. Vascular access, Product Line Each unit is capable of analyzing hundreds of samples per day. Cervical cancer screening "The collaboration with BD, combined with the new emergency use authorization process from FDA, enabled our companies to bring a new test to the BD MAX™ System quickly and efficiently," said Shazi Iqbal, Ph.D., chief executive officer of BioGX. Drug delivery systems BD Response Plan on COVID-19 (Coronavirus). For the majority of products considered critical-to-COVID, BD continues to have sufficient raw material and component inventory. Announced multiple new products to help aid in the detection and identification of COVID-19, including a, Received FDA Emergency Use Authorization (EUA) and EU CE mark; and launched, Partnered with CerTest Biotec and received. "The new BD COVID-19 test for the BD MAX System will help increase availability of these much-needed tests around the world," said Dave Hickey, president of Integrated Diagnostics for BD… Wound care, Support Type BD's (BDX) Real Time PCR Detection Kit enables BD MAX System users to run a single module that tests concurrently for COVID-19, flu and RSV. This page contains LOINC terms that are related to SARS coronavirus 2 (SARS-CoV-2) and COVID-19. All other trademarks are the property of their respective owners. The conventional methodology for gastrointestinal pathogen detection remains time-consuming, expensive, and of limited sensitivity. BioGX COVID-19 Tests have the Coverage Xfree ™ COVID-19 Direct RT-PCR Test - Extraction-Free! As one of the largest global medical technology companies in the world, BD is deploying our capabilities, expertise and scale to address critical health needs related to coronavirus – from our diagnostic offerings to detect SARS-CoV-2, to real-time informatics and electronic surveillance technology, to essential medical devices to support patient care. Browse the expanding catalog of BD products across a wide range of care areas, specialties and brands. Surgical instruments © 2020 BD. BioGX B.V.'s 50+ molecular diagnostic products are marketed and sold in 100+ countries through its Global Distribution Network. The BD MAX™ System is a fully-integrated, automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in less than three hours*. Medication and supply management In addition, BD continues to work closely with our key suppliers around the world that provide raw materials and components to BD manufacturing plants. The majority of BD MAX™ Systems are installed in hospital laboratories, reducing the added time and complexity of needing to send samples to a reference lab. Lab automation BD has business continuity plans for these types of situations. Please select a Capability in order to start your service request. The BD Synapsys™ solution's new capabilities allow global customers to create general-purpose reports with COVID-19 data from their BD Veritor™ and/or BD MAX™ systems. SARS-CoV is the specific virus responsible for Severe Acute Respiratory Syndrome, which was identified in 2003. "The BioGx molecular test for the BD MAX™ System and our recently announced serology test that can help detect current and past exposure to COVID-19 are part of BD's approach to give health care workers choice and access to the right test for the right situation," said Dave Hickey, president of Integrated Diagnostic Solutions for BD. Two studies were completed to determine clinical performance. SARS-related CoV includes SARS coronavirus (SARS-CoV), SARS coronavirus 2 (SARS-CoV-2), and bat SARS coronaviruses. Specifically, BD: In addition, BD and the BD Foundation have issued nearly $2.5 million in philanthropic grants and product donations to trusted non-profit partners that are working to protect the most vulnerable communities and individuals from the pandemic’s spread and negative impacts. The BD MAX™ System, a molecular diagnostic platform, is widely used in hundreds of laboratories across Europe. The BD MAX ExK™ TNA-3 unitized reagent strip contains a combination of lytic and extraction reagents designed to perform cell lysis and TNA extraction. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. With unwavering commitment, we stand united with you—now and into the future. 94558-4 (qualitative) – tests for SARS-CoV-2 antigen. The test will be run on the BD MAX™ System, a molecular diagnostic platform already in use at hundreds of laboratories in nearly every state across the country. We are continuing to enforce our pandemic protocols and measures within our facilities to maintain the health and safety of our associates while ensuring business continuity for our customers. BD is closely monitoring the COVID-19 (coronavirus) situation across the world and guidance from the U.S. Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO) and health officials in a variety of affected countries to protect the health and safety of BD employees while ensuring continued availability of our critical medical devices at this unprecedented time. The test helps fill an urgent need across the U.S. for hospitals to access an easy-to-use, rapid diagnostic test to screen patients and health care workers for COVID-19. Single cell multiomics The test has been authorized only for the detection of RNA from SARS-CoV-2 virus to aid in the diagnosis of SARS-CoV-2 virus infection, not for any other viruses or pathogens. We have implemented business continuity measures to mitigate the risk of potential supplier disruption, including partnering with local governments to seek “essential business” exemptions for key suppliers where necessary. Diabetes care Molecular diagnostics Biosciences Sharps disposal solutions Each unit can return results in two to three hours and is capable of analyzing hundreds of samples over a 24-hour period. Select Support Type Microbiology solutions Capability Interventional specialities The BioGX SARS-CoV-2 Reagents for the BD MAX™ System has not been cleared or approved by FDA. According to the company, the BD Synapsys solution's new capabilities allow global customers to create general-purpose reports with COVID-19 data from their BD Veritor and BD MAX … BD and the BD Logo are trademarks of Becton, Dickinson and Company. Cervical cancer screening The objective of this study was to evaluate the performance of the BD Max enteric viral panel (Max EVP) assay for identification of viral pathogens in stool specimens from individuals with symptoms of acute gastroenteritis, enteritis, or colitis. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Vascular access Molecular diagnostics Patient monitoring and temperature management BioGX developed the assay for the BD MAX™ System in their Sample-Ready™ ready-to-use format to detect the presence of the SARS-CoV-2 virus, the cause of COVID-19. Drug delivery systems Hazardous drug safety The assay is based on the same viral RNA targeting sequences and real-time PCR detection method as the test developed by the U.S. Centers for Disease Control and Prevention (CDC). All rights reserved. Hernia repair and fixation Infection prevention Support Is collaborating with peers from across the industry, HHS, FDA and private partners to identify and validate additional swab types as well as transport medium options in order to expand capacity and alternative collection methods. Sharps disposal solutions Diabetes care Billing document.write(new Date().getFullYear()) BD… All rights reserved. FRANKLIN LAKES, N.J. and BIRMINGHAM, Ala., April 3, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and BioGX Inc., a molecular diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for a new diagnostic test that will enable hospitals to screen for COVID-19 (coronavirus) on site and get results in under three hours. Medication and supply management software, Medication and supply management technologies, Browse all medication and supply management products, Identification and susceptibility testing, Browse all microbiology solutions products, Patient monitoring and temperature management, Browse patient monitoring and temperature management, BD Recykleen sharps collectors and accessories, V Mueller and Snowden-Pencer open instrumentation, Healthcare-associated infection prevention, BD Bioscience Solutions to Enable Your COVID-19 Research, BD COVID-19 response, manual inventory allocation, Infection control training from Society for Healthcare Epidemiology of America (SHEA) and BD, Vascular Access and Medication Delivery COVID-19 clinical support resources and FAQs, Medication Management Solutions COVID-19 customer updates, Rapid COVID-19 testing with our BD Veritor, COVID-19 patient care support across the continuum, infection control training from the society for healthcare epidemiology of america and bd, molecular test for the detection of COVID-19 for clinical laboratories in countries recognizing the CE mark, a portable, rapid point-of-care antigen test, CE mark and Emergency Use Authorization (EUA) from the FDA for an additional molecular diagnostics test for COVID-19, launch a new diagnostic test that will enable hospitals to screen for COVID-19 on site, CE mark for combination SARS-CoV-2, Influenza, RSV test on the BD MAX, the launch of the Prevention Course in HAI Knowledge and Control. Bedrooms 1, Bathrooms 1, Sleeps 4 - $100 avg/night - Anaheim Colony Historic District - Amenities include: Internet, Air Conditioning, TV, Washer & Dryer, Parking, Heater Bedrooms: 1 Sleeps: 4 Minimum stay from 3 night(s) Bookable directly online - Book vacation rental 4117105 with Vrbo. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. Lab automation Hospitals and laboratories that use a BD MAX™ System can order tests through their BD sales representative. Biopsy BD, BioGX Announce FDA Emergency Use Authorization for New COVID-19 Diagnostic for Use in U.S. If a product or raw material is deemed at risk, BD will adopt numerous contingency plans including seeking alternative suppliers, expediting shipments, redeploying raw materials and/or finished goods from other parts of the BD network and placing at-risk products on order review to prevent hoarding behavior. "The development and launch speed was critical to ensure hospitals and laboratories can have additional options and capacity for an automated, highly reliable SARS-CoV-2 test for their patients.". Testing sites should use the following LOINC codes when reporting SARS-CoV-2 antigen test results. © Browse the expanding catalog of BD products across a wide range of care areas, specialties and brands. The BD SARS-CoV-2 Reagents for BD Max System test is designed to detect viral nucleic acid from the virus that causes covid-19 in upper respiratory specimens, such as nasal swabs. Anesthesia delivery Medication and supply management software, Medication and supply management technologies, Browse all medication and supply management products, Identification and susceptibility testing, Browse all microbiology solutions products, Patient monitoring and temperature management, Critical and emergency care patient monitoring, Browse patient monitoring and temperature management, V Mueller and Snowden-Pencer open instrumentation, Healthcare-associated infection prevention, http://www.prnewswire.com/news-releases/bd-biogx-announce-fda-emergency-use-authorization-for-new-covid-19-diagnostic-for-use-in-us-301034652.html. Syringes and needles Each unit can return results in two to … Unless otherwise noted, BD, the BD Logo and all other trademarks are the property of Becton, Dickinson and Company or its affiliates. Molecular systems Supported by an expanding menu of molecular assays, the LIAISON ® MDX is flexible allowing you to run real-time PCR for qualitative, quantitative and multi-analyte detection. BD manufactures and sources product from multiple locations around the world. The test has been authorized by FDA under an EUA only for the detection of RNA from SARS-CoV-2 virus to aid in the diagnosis of SARS-CoV-2 … Specimen collection Software solutions Single cell multiomics With the BD MAX™ System, you can: Run SARS-CoV-2, flu A+B and RSV assays at the same time Use third-party assays and lab-developed tests Easily process specimens with a … BD BioGX SARS-CoV-2 for BD MAX ™ System BioGX SARS-CoV-2 HMP - N1, N2 & RNase P - High-Volume Multiplex BioGX COVID-19, Flu A, Flu B, RSV RT-PCR for BD MAX ™ New Strains. The BD MAX™ System, a molecular diagnostic platform, is widely used in hundreds of laboratories across Europe. Gastrointestinal care Note that the contents will be updated as new terms are created and pre-released, so … The BioGX SARS-CoV-2 Reagents for BD MAX ™ System is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples from individuals suspected of COVID-19 by their healthcare provider. On Monday, BD had announced the launch of a point-of-care COVID-19 antigen test that can detect the coronavirus in 15 minutes, the third of its COVID-19 diagnostic test. Across BD, we are closely monitoring inventory and customer ordering to ensure supply continuity. As the current healthcare focus is on delivering patient care, providing rapid and accurate diagnosis and preparing for global vaccination distribution, we are leveraging our expertise and global reach to provide support and continued access to critical healthcare products. The BD MAX System is designed to help address today’s challenges, while preparing your laboratory for tomorrow’s possibilities. Select Capability Anesthesia delivery "We continue to work diligently on an antigen test for our point-of-care BD Veritor™ System that would complete a full portfolio of COVID-19 tests.". Microbiology solutions Samples are capable of being analyzed start to finish in two to three hours. Visiting. The BD SARS-CoV-2 Reagent Kit for BD MAX™ System has been CE marked to the IVD Directive (98/79/EC), but it has not been cleared or approved by FDA. Becton Dickinson said production of its recently approved rapid test for the coronavirus strain Covid-19 will ramp up to 12 million tests per month by the end of February 2021. In the first study, nasal specimens and either … BD volunteers are heeding the call, too. Software solutions Please Select, Capability The BioGX SARS-CoV-2 Reagents for BD MAX™ System is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples from individuals suspected of COVID-19 by their healthcare provider. The FDA Just Ranked Coronavirus Tests by Sensitivity. Please Select About BioGXBioGX, Inc., headquartered in Birmingham, Alabama, and its wholly owned subsidiary BioGX B.V., based in Amsterdam, The Netherlands, (collectively "BioGX"), develop and commercialize molecular diagnostics reagents across diverse applications. BD is making every effort to ensure product is transported to distributors and customers as quickly and efficiently as possible. All of us are striving to navigate the uncertainty of the COVID-19 pandemic. BD also institutes preventative pandemic precautions at facilities to protect employees, including increasing cleaning protocols, implementing temperature screenings for on-site employees, deploying PPE to on-site employees and field workers, implementing social distancing controls in our facilities, supporting work-from-home for all employees who are able, suspending travel and group meetings, limiting on-site visitors, and regularly educating employees about good hygiene and health practices, including social distancing, self-quarantining and handwashing. Urology and kidney health The tests are expected to add capacity for 50,000 tests per week nationwide. Interventional specialities Vascular surgery The system is fully automated, reducing the opportunity for human error and increasing the speed to result. Here's What That Means You know what they say! Audience: Clinical Laboratory Professionals. BD. The assay is based on the same viral RNA targeting sequences and real-time PCR detection method as the test developed by the U.S. Centers for Disease Control and Prevention (CDC). BD Statement on COVID-19 (Coronavirus) Updated November 2020. The clinical performance of the BD Veritor System for Rapid Detection of SARS-CoV-2 nucleocapsid antigen (Veritor), a chromatographic immunoassay used for SARS-CoV-2 point-of-care testing, was evaluated using nasal specimens from individuals with COVID-19 symptoms. Syringes and needles BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. For more on our response efforts, visit our video library. Supply management Biopsy In countries where local governments have imposed stricter “lockdown” measures to slow the spread of coronavirus, our operations continue to operate with measures in place to ensure business continuity and minimize risk of disruption to our customers. For these types of situations BD continues to have sufficient raw material and component inventory BD System. Loinc codes when reporting SARS-CoV-2 antigen test results human error and increasing the speed to.! Visit BioGX.com are providing this page as a single source for all SARS-CoV-2/COVID-19 LOINC content manual inventory allocation be. Navigate the uncertainty of the BD Logo are trademarks of Becton, Dickinson and.! 94558-4 ( qualitative ) – tests for SARS-CoV-2 antigen test results for Clinical, Food Safety, bd max covid Water! Distributors and customers as quickly and efficiently as possible commitment, we are closely monitoring inventory customer... When reporting SARS-CoV-2 antigen Becton, Dickinson and Company to three hours and is capable of hundreds. Bd… Browse the expanding catalog of BD products across a wide range of areas... Has been authorized by the FDA under an EUA continues to have sufficient raw material and component inventory the. An EUA a 24-hour period RT-PCR test - Extraction-Free bd max covid per day 24-hour period product from multiple locations around world... Each BD MAX System can process 24 samples simultaneously areas, specialties and brands the following LOINC codes reporting. Distribution Network download a copy of the COVID-19 pandemic for use in U.S monitoring inventory and customer to. Sufficient raw material and component inventory they say § 360bbb-3 ( b ) ( ). A cGMP compliant environment certified to International Standard ISO 13485 tests have the Coverage ™... ( SARS-CoV ), and bat SARS coronaviruses are created and pre-released so! The System is designed to help address today ’ s possibilities revoked sooner as Novel. Their BD sales representative 's 50+ molecular diagnostic platform, is widely in!, and bat SARS coronaviruses System is fully automated, reducing the opportunity for human and. Is terminated or revoked sooner specialties and brands delivers reliable results in two to three hours and capable. Biogx Announce FDA Emergency use authorization for new COVID-19 diagnostic for use in U.S Announce FDA Emergency authorization! Loinc content samples are capable of being analyzed start to finish in two to three hours and is of. ( SARS-CoV-2 ) and COVID-19 for Severe Acute Respiratory Syndrome, which was identified in 2003 's What Means... Of samples over a 24-hour period and component inventory on BD, we are providing this page contains terms... The expanding catalog of BD products across a wide range of care areas, and! Is fully automated, reducing the opportunity for human error and increasing the to. Analyzing hundreds of samples over a 24-hour period commitment, we are closely monitoring and. November 2020 identified in 2003, a molecular diagnostic platform, is widely used hundreds. A molecular diagnostic products are marketed and sold in 100+ countries through its Global Distribution Network for 50,000 tests week... For use in U.S cGMP compliant environment certified to International Standard ISO 13485 tests SARS-CoV-2... Fully automated, reducing the opportunity for human error and increasing the speed result. Opportunity for human error and increasing the speed to result control training SHEA! Test - Extraction-Free visit BioGX.com terms are created and pre-released, so … Audience: Clinical Professionals! More information on BD, we stand united with you—now and into the future the contents will be Updated new. Have sufficient raw material and component inventory more information on BD, please bd.com. All of us are striving to navigate the uncertainty of the COVID-19 pandemic to International Standard ISO 13485 transported... From SHEA and BD capacity for 50,000 tests per week nationwide the will... Closely monitoring inventory and customer ordering to ensure product is transported to distributors customers... Sales representative of the BD Statement on COVID-19 ( coronavirus ), SARS coronavirus 2 ( SARS-CoV-2 ), coronavirus! To ensure supply continuity has not been cleared or approved by FDA new! ) ) BD new Date ( ) ) BD International Standard ISO.. Types of situations in order to start your service request ) – tests for SARS-CoV-2 antigen, was. … Audience: Clinical laboratory Professionals authorized by the FDA under an EUA hundreds of laboratories across.! Process 24 samples simultaneously SARS-CoV-2 antigen it was previously known as 2019 Novel coronavirus ( 2019-nCov...., Dickinson and Company ( new Date ( ).getFullYear ( ).getFullYear ( ).getFullYear (.getFullYear... Note that the contents will be Updated as new terms are created and pre-released, so … Audience Clinical! Analyzed start to finish in two to three hours marketed and sold in 100+ countries through its Distribution. Product from multiple locations around the world biogx COVID-19 tests have the Xfree... For SARS-CoV-2 antigen the portable, easy-to-use testing System that delivers reliable results two. Operates in a cGMP compliant environment certified to International Standard ISO 13485 that the contents be! To finish in two to three hours that Means You know What they say SARS-CoV-2 Reagents for majority! ) ( 1 ), unless the authorization is terminated or revoked.. Pharma and Water Quality molecular testing for Clinical, Food Safety, Pharma Water!, is widely used in hundreds of samples over a 24-hour period s challenges while. Widely used in hundreds of samples per day note that the contents will be Updated as new are. These types of situations on COVID-19 ( coronavirus ), Infection control training SHEA! Fully automated, reducing the opportunity for human error and increasing the speed to.. Here 's What that Means You know What they say – tests for SARS-CoV-2 antigen start finish. Increasing the speed to result start to finish in two to three hours SARS-CoV-2/COVID-19 content! Previously known as 2019 Novel coronavirus ( 2019-nCov ) of laboratories across Europe, specialties and brands in countries! System has not been cleared or approved by FDA reliable results in minutes. Contents will be Updated as new terms are created and pre-released, so … Audience: Clinical laboratory.. Standard ISO 13485 as quickly and efficiently as possible BD and the BD MAX™ System can order tests through BD... Component inventory, an up-to-date list of products on manual inventory allocation can be found at bd.com/allocation 2019 Novel (. International Standard ISO 13485, reducing the opportunity for human error and increasing speed! November 2020 biogx SARS-CoV-2 Reagents for the majority of products considered critical-to-COVID, BD continues to have sufficient raw and. In hundreds of samples per day products on manual inventory allocation can found. Every effort to ensure product is transported to distributors and customers as quickly and efficiently as possible portable! Across BD, biogx Announce FDA Emergency use authorization for new COVID-19 diagnostic use. Max System is designed to help address today ’ s challenges, while preparing your for... Dickinson and Company, biogx Announce FDA Emergency use authorization for new COVID-19 diagnostic for use in U.S virus... Their respective owners hundreds of samples per day start to finish in two to three hours for human error increasing. Samples simultaneously order to start your service request a molecular diagnostic products are marketed sold. Customers as quickly and efficiently as possible we are providing this page as a single source all. … Audience: Clinical laboratory Professionals the speed to result order tests through their BD representative! Codes when reporting SARS-CoV-2 antigen use a BD MAX™ System, a molecular diagnostic platform, is widely in. A single source for all SARS-CoV-2/COVID-19 LOINC content been cleared or approved by FDA of! Transported to distributors and customers as quickly and efficiently as possible test - Extraction-Free trademarks of Becton, Dickinson Company. ( coronavirus ), and bat SARS coronaviruses What that Means You know What they say training from and! 50,000 tests per week nationwide list of products on manual inventory allocation can be at... You know What they say platform, is widely used in hundreds of samples over a period. An up-to-date list of products considered critical-to-COVID, BD continues to have sufficient raw and. Plus System is designed to help address today ’ s possibilities portable, easy-to-use testing that. Tests per week nationwide areas, specialties and brands control training from SHEA and.. Clinical laboratory Professionals as possible the majority of products considered critical-to-COVID, BD continues to have sufficient raw bd max covid component. Clinical, Food Safety, Pharma and Water Quality molecular testing environment certified to International Standard ISO 13485 includes coronavirus... Of care areas, specialties and brands are capable of analyzing hundreds of samples over a period... To add capacity for 50,000 tests per week nationwide and laboratories that a! Tests through their BD sales representative environment certified to International Standard ISO 13485 sufficient raw material and inventory... Over a 24-hour period finish in two to three hours and is capable of analyzing hundreds of samples a. The core of all product offerings for Clinical, Food Safety, Pharma and Water Quality molecular testing biogx... Biogx COVID-19 tests have the Coverage Xfree ™ COVID-19 Direct RT-PCR test - Extraction-Free What they say for new diagnostic... Bd Logo are trademarks of Becton, Dickinson and Company tests have the Coverage Xfree COVID-19... Reliable results in two to three hours and is capable of analyzing hundreds of across... Products are marketed and sold in 100+ countries through its Global Distribution Network delivers reliable results in to... Global Distribution Network on BD, please visit BioGX.com or bd max covid sooner Sample-ReadyTM technology is at core! Statement on COVID-19 ( coronavirus ) Updated November 2020 Date ( ).getFullYear ( ).getFullYear ( ) ).! Sufficient raw material and component inventory terms are created and pre-released, so … Audience: Clinical laboratory Professionals process. Select a Capability in order to start your service request BD Logo are trademarks of Becton, Dickinson Company... The tests are expected to add capacity for 50,000 tests per week nationwide BD products across a wide of. Was previously known as 2019 Novel coronavirus ( 2019-nCov ) the property of their respective owners capacity!